skip to content
Phosphodiesterases as drug targets Preview this item
ClosePreview this item
Checking...

Phosphodiesterases as drug targets

Author: Sharron H Francis; Marco Conti, Prof.; Miles D Houslay
Publisher: Heidelberg : Springer, ©2011.
Series: Handbook of experimental pharmacology, v. 204.
Edition/Format:   Print book : EnglishView all editions and formats
Summary:
Cyclic nucleotide phosphodiesterases (PDEs) are promising targets for pharmacological intervention. Multiple PDE genes, isoform diversity, selective expression and compartmentation of the isoforms, and an array of conformations of PDE proteins are properties that challenge development of drugs that selectively target this class of enzymes. Novel characteristics of PDEs are viewed as unique opportunities to increase  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Document Type: Book
All Authors / Contributors: Sharron H Francis; Marco Conti, Prof.; Miles D Houslay
ISBN: 9783642179686 3642179681 9783642179693 364217969X
OCLC Number: 748763467
Description: xvi, 519 pages : illustrations.
Contents: Phosphodiesterase inhibitors: history of pharmacology --
Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action --
Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics --
Structural insight into the substrate specificity of phosphodiesterases --
Fission yeast-based platform for phosphodiesterase inhibitor HTSs and analysis of phosphodiesterase activity --
GAF-tandem domain of phosphodiesterase 5 as a potential drug target --
Small molecule allosteric modulators of phosphodiesterase 4 --
Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases --
Phosphodiesterases as targets for intermittent claudication --
Phosphodiesterase inhibition in heart failure --
Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension --
Role of phosphodiesterases in adult-onset pulmonary artery hypertension --
Treatment of erectile dysfunction --
and lower urinary tract symptoms by phosphodiesterase inhibitors --
Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of Duchenne muscular dystrophy --
Phosphodiesterases as targets for modulating t-cell responses --
Cyclic nucleotides and phosphodiesterases in monocytic differentiation --
Phosphodiesterase inhibitors in the treatment of inflammatory diseases --
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies --
Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders --
Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases.
Series Title: Handbook of experimental pharmacology, v. 204.
Responsibility: Sharron H. Francis, Marco Conti, Miles D. Houslay, editors.

Abstract:

Cyclic nucleotide phosphodiesterases (PDEs) are promising targets for pharmacological intervention. Along with its coverage of fresh and emerging ideas in this key field, the book examines all the  Read more...

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/748763467> # Phosphodiesterases as drug targets
    a schema:Book, schema:CreativeWork ;
   library:oclcnum "748763467" ;
   library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/1004366138#Place/heidelberg> ; # Heidelberg
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/gw> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/drug_discovery> ; # Drug Discovery
   schema:about <http://dewey.info/class/615.19/e23/> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphodiesterasen> ; # Phosphodiesterasen
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/arzneimitteldesign> ; # Arzneimitteldesign
   schema:about <http://id.worldcat.org/fast/898769> ; # Drugs--Analysis
   schema:about <http://id.loc.gov/authorities/subjects/sh85039722> ; # Drugs--Analysis
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphodiesterase_inhibitors_therapeutic_use> ; # Phosphodiesterase Inhibitors--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/pharmakotherapie> ; # Pharmakotherapie
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/pharmakologie> ; # Pharmakologie
   schema:about <http://id.worldcat.org/fast/1061400> ; # Phosphodiesterases
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphodiesterasehemmer> ; # Phosphodiesterasehemmer
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphodiesterase_inhibitors_pharmacology> ; # Phosphodiesterase Inhibitors--pharmacology
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphoric_diester_hydrolases_therapeutic_use> ; # Phosphoric Diester Hydrolases--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphoric_diester_hydrolases_pharmacology> ; # Phosphoric Diester Hydrolases--pharmacology
   schema:bookFormat bgn:PrintBook ;
   schema:contributor <http://viaf.org/viaf/65793262> ; # Sharron H. Francis
   schema:contributor <http://viaf.org/viaf/51759249> ; # Miles D. Houslay
   schema:contributor <http://viaf.org/viaf/13017618> ; # Prof. Marco Conti
   schema:copyrightYear "2011" ;
   schema:datePublished "2011" ;
   schema:description "Phosphodiesterase inhibitors: history of pharmacology -- Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action -- Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics -- Structural insight into the substrate specificity of phosphodiesterases -- Fission yeast-based platform for phosphodiesterase inhibitor HTSs and analysis of phosphodiesterase activity -- GAF-tandem domain of phosphodiesterase 5 as a potential drug target -- Small molecule allosteric modulators of phosphodiesterase 4 -- Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases -- Phosphodiesterases as targets for intermittent claudication -- Phosphodiesterase inhibition in heart failure -- Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension -- Role of phosphodiesterases in adult-onset pulmonary artery hypertension -- Treatment of erectile dysfunction -- and lower urinary tract symptoms by phosphodiesterase inhibitors -- Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of Duchenne muscular dystrophy -- Phosphodiesterases as targets for modulating t-cell responses -- Cyclic nucleotides and phosphodiesterases in monocytic differentiation -- Phosphodiesterase inhibitors in the treatment of inflammatory diseases -- Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies -- Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders -- Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases."@en ;
   schema:description "Cyclic nucleotide phosphodiesterases (PDEs) are promising targets for pharmacological intervention. Multiple PDE genes, isoform diversity, selective expression and compartmentation of the isoforms, and an array of conformations of PDE proteins are properties that challenge development of drugs that selectively target this class of enzymes. Novel characteristics of PDEs are viewed as unique opportunities to increase specificity and selectivity when designing novel compounds for certain therapeutic indications. This chapter provides a summary of the major concepts related to the design and use of PDE inhibitors."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/1004366138> ;
   schema:inLanguage "en" ;
   schema:isPartOf <http://worldcat.org/issn/0171-2004> ; # Handbook of experimental pharmacology ;
   schema:name "Phosphodiesterases as drug targets"@en ;
   schema:productID "748763467" ;
   schema:publication <http://www.worldcat.org/title/-/oclc/748763467#PublicationEvent/heidelberg_springer_2011> ;
   schema:publisher <http://experiment.worldcat.org/entity/work/data/1004366138#Agent/springer> ; # Springer
   schema:workExample <http://worldcat.org/isbn/9783642179686> ;
   schema:workExample <http://worldcat.org/isbn/9783642179693> ;
   umbel:isLike <http://bnb.data.bl.uk/id/resource/GBB0E3315> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/748763467> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphodiesterase_inhibitors_pharmacology> # Phosphodiesterase Inhibitors--pharmacology
    a schema:Intangible ;
   schema:name "Phosphodiesterase Inhibitors--pharmacology"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphodiesterase_inhibitors_therapeutic_use> # Phosphodiesterase Inhibitors--therapeutic use
    a schema:Intangible ;
   schema:name "Phosphodiesterase Inhibitors--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphodiesterasehemmer> # Phosphodiesterasehemmer
    a schema:Intangible ;
   schema:name "Phosphodiesterasehemmer"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphoric_diester_hydrolases_pharmacology> # Phosphoric Diester Hydrolases--pharmacology
    a schema:Intangible ;
   schema:name "Phosphoric Diester Hydrolases--pharmacology"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1004366138#Topic/phosphoric_diester_hydrolases_therapeutic_use> # Phosphoric Diester Hydrolases--therapeutic use
    a schema:Intangible ;
   schema:name "Phosphoric Diester Hydrolases--therapeutic use"@en ;
    .

<http://id.loc.gov/authorities/subjects/sh85039722> # Drugs--Analysis
    a schema:Intangible ;
   schema:name "Drugs--Analysis"@en ;
    .

<http://id.worldcat.org/fast/1061400> # Phosphodiesterases
    a schema:Intangible ;
   schema:name "Phosphodiesterases"@en ;
    .

<http://id.worldcat.org/fast/898769> # Drugs--Analysis
    a schema:Intangible ;
   schema:name "Drugs--Analysis"@en ;
    .

<http://viaf.org/viaf/13017618> # Prof. Marco Conti
    a schema:Person ;
   schema:familyName "Conti" ;
   schema:givenName "Marco" ;
   schema:name "Prof. Marco Conti" ;
    .

<http://viaf.org/viaf/51759249> # Miles D. Houslay
    a schema:Person ;
   schema:familyName "Houslay" ;
   schema:givenName "Miles D." ;
   schema:name "Miles D. Houslay" ;
    .

<http://viaf.org/viaf/65793262> # Sharron H. Francis
    a schema:Person ;
   schema:familyName "Francis" ;
   schema:givenName "Sharron H." ;
   schema:name "Sharron H. Francis" ;
    .

<http://worldcat.org/isbn/9783642179686>
    a schema:ProductModel ;
   schema:isbn "3642179681" ;
   schema:isbn "9783642179686" ;
    .

<http://worldcat.org/isbn/9783642179693>
    a schema:ProductModel ;
   schema:isbn "364217969X" ;
   schema:isbn "9783642179693" ;
    .

<http://worldcat.org/issn/0171-2004> # Handbook of experimental pharmacology ;
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/748763467> ; # Phosphodiesterases as drug targets
   schema:issn "0171-2004" ;
   schema:name "Handbook of experimental pharmacology ;" ;
   schema:name "Handbook of experimental pharmacology," ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.